Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.

PubWeight™: 0.79^‹?›

🔗 View Article (PMID 26371113)

Published in Eur Heart J on September 14, 2015

Authors

Dragos Vinereanu¹, Susanna R Stevens², John H Alexander², Sana M Al-Khatib², Alvaro Avezum³, Marıa Cecilia Bahit⁴, Christopher B Granger², Renato D Lopes², Sigrun Halvorsen⁵, Michael Hanna⁶, Steen Husted⁷, Elaine M Hylek⁸, Andrei D Mărgulescu⁹, Lars Wallentin¹⁰, Dan Atar¹¹

Author Affiliations

1: University of Medicine and Pharmacy Carol Davila, Bucharest, Romania Department of Cardiology, University and Emergency Hospital of Bucharest, 169 Splaiul Independentei, Sector 5, Bucharest, Romania vinereanu@gmail.com.
2: Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
3: Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil.
4: INECO Neurociencias Oroño, Rosario, Argentina.
5: Oslo University Hospital and University of Oslo, Oslo, Norway.
6: Bristol-Myers Squibb, Princeton, NJ, USA.
7: Hospital Unit West and Aarhus University Hospital, Aarhus, Denmark.
8: Boston University Medical Center, Boston, MA, USA.
9: University of Medicine and Pharmacy Carol Davila, Bucharest, Romania Department of Cardiology, University and Emergency Hospital of Bucharest, 169 Splaiul Independentei, Sector 5, Bucharest, Romania.
10: Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
11: Department of Cardiology B, Oslo University Hospital, and Institute of Clinical Sciences, University of Oslo, Oslo, Norway.

Associated clinical trials:

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) | NCT00412984

Articles citing this ↘

Reducing the risk of venous thromboembolism using apixaban - patient perspectives and considerations. Should more attention be given to females? Patient Prefer Adherence (2016) 0.75

Atrial fibrillation in women: treatment. Nat Rev Cardiol (2016) 0.75

Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart (2017) 0.75

Articles by these authors ⇆

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet (2016) 3.02

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J (2014) 2.32

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet (2015) 1.81

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J (2014) 1.51

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J (2014) 1.50

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J (2016) 1.14

Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet (2017) 0.98

Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. Lancet Diabetes Endocrinol (2017) 0.97

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J (2014) 0.94

Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke (2015) 0.87

Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? Am Heart J (2014) 0.83

Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med (2010) 0.81

Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother (2015) 0.80

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. JAMA (2015) 0.79

How can we optimize the processes of care for acute coronary syndromes to improve outcomes? Am Heart J (2014) 0.78

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J (2016) 0.76

Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol (2013) 0.76

Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. Thromb Res (2016) 0.76

Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. Eur J Heart Fail (2016) 0.76

Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". Circulation (2014) 0.75

Tobacco control environment: cross-sectional survey of policy implementation, social unacceptability, knowledge of tobacco health harms and relationship to quit ratio in 17 low-income, middle-income and high-income countries. BMJ Open (2017) 0.75

Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol (2016) 0.75

Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. Cardiovasc Drugs Ther (2017) 0.75

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovasc Drugs Ther (2017) 0.75

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J (2017) 0.75

Assessing global risk factors for non-fatal injuries from road traffic accidents and falls in adults aged 35-70 years in 17 countries: a cross-sectional analysis of the Prospective Urban Rural Epidemiological (PURE) study. Inj Prev (2015) 0.75

Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough? Eur Heart J (2017) 0.75

Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. Int J Cardiol (2016) 0.75

Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. Eur J Heart Fail (2016) 0.75

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J (2017) 0.75